


## **CLAIMS:**

1. An antibody-drug conjugate of Formula (I):



wherein

Ab is an internalizing anti-folate receptor alpha antibody or internalizing antigen-binding fragment thereof comprising three heavy chain complementarity determining regions (HCDRs) comprising amino acid sequences of SEQ ID NO:2 (HCDR1), SEQ ID NO:3 (HCDR2), and SEQ ID NO:4 (HCDR3); and three light chain complementarity determining regions (LCDRs) comprising amino acid sequences of SEQ ID NO:7 (LCDR1), SEQ ID NO:8 (LCDR2), and SEQ ID NO:9 (LCDR3), as defined by the Kabat numbering system; or three heavy chain complementarity determining regions (HCDRs) comprising amino acid sequences of SEQ ID NO:13 (HCDR1), SEQ ID NO:14 (HCDR2), and SEQ ID NO:15 (HCDR3); and three light chain complementarity determining regions (LCDRs) comprising amino acid sequences of SEQ ID NO:16 (LCDR1), SEQ ID NO:17 (LCDR2), and SEQ ID NO:18 (LCDR3), as defined by the IMGT numbering system;

D is eribulin;


L is a cleavable linker comprising Mal-(PEG)<sub>2</sub>-Val-Cit-pAB; and

*p* is an integer from 1 to 8.

2. The antibody-drug conjugate of claim 1, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:23, and a light chain variable region comprising an amino acid sequence of SEQ ID NO:24; and wherein *p* is an integer from 3 to 4.
3. The antibody-drug conjugate of claim 1, wherein the antibody or antigen-binding fragment comprises a human IgG1 heavy chain constant domain and a human Ig kappa light chain constant domain.
4. A pharmaceutical composition comprising the antibody-drug conjugate of claim 1, and a pharmaceutically acceptable carrier.

5. A composition comprising multiple copies of the antibody-drug conjugate of claim 1, wherein the average  $p$  of the antibody-drug conjugates in the composition is from about 3.2 to about 4.4.

6. A composition comprising multiple copies of an antibody-drug conjugate of Formula (I):



wherein

Ab is an internalizing anti-folate receptor alpha antibody or internalizing antigen-binding fragment thereof comprising three heavy chain complementarity determining regions (HCDRs) comprising amino acid sequences of SEQ ID NO:2 (HCDR1), SEQ ID NO:3 (HCDR2), and SEQ ID NO:4 (HCDR3); and three light chain complementarity determining regions (LCDRs) comprising amino acid sequences of SEQ ID NO:7 (LCDR1), SEQ ID NO:8 (LCDR2), and SEQ ID NO:9 (LCDR3), as defined by the Kabat numbering system; or three heavy chain complementarity determining regions (HCDRs) comprising amino acid sequences of SEQ ID NO:13 (HCDR1), SEQ ID NO:14 (HCDR2), and SEQ ID NO:15 (HCDR3); and three light chain complementarity determining regions (LCDRs) comprising amino acid sequences of SEQ ID NO:16 (LCDR1), SEQ ID NO:17 (LCDR2), and SEQ ID NO:18 (LCDR3), as defined by the IMGT numbering system;

D is eribulin;

L is a cleavable linker comprising Mal-(PEG)<sub>2</sub>-Val-Cit-pAB; and

$p$  is the average number of -L-D moieties per Ab, wherein the average  $p$  of the antibody-drug conjugates in the composition is from about 3.6 to about 4.4.

7. The composition of claim 6, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:23, and a light chain variable region comprising an amino acid sequence of SEQ ID NO:24.

8. Use of a therapeutically effective amount of the antibody-drug conjugate of claim 1, in the manufacture of a medicament for the treatment of a cancer that expresses folate receptor alpha.

9. The use of claim 8, wherein the cancer is a gastric cancer, a serous ovarian cancer, a clear cell ovarian cancer, a non-small cell lung cancer, a colorectal cancer, a triple negative breast cancer, an endometrial cancer, a lung carcinoid, an osteosarcoma, a bladder cancer, or an urothelial cell carcinoma.

10. The use of claim 8, wherein the cancer is a serous endometrial carcinoma.

11. Use of a therapeutically effective amount of the antibody-drug conjugate of claim 1, in the manufacture of a medicament for reducing or inhibiting growth of a folate receptor alpha-expressing tumor.

12. A therapeutically effective amount of the antibody-drug conjugate of claim 1, for use in therapy.